Conditions & diseases

tumor

Observed in 589 articles across 20 journals.

Steady

Latest share0.61%

Change vs baseline-0.01 pp

Months observed13

Latest monthJul 2026

Portfolio article share

Attention over this snapshot

13 monthly points

Journal breadth

Where it appears

Journal for ImmunoTherapy of Cancer497
BMJ Case Reports27
Gut24
Journal of Clinical Pathology6
Journal of NeuroInterventional Surgery6
BMJ Oncology4
BMJ Open4
British Journal of Ophthalmology3
Journal of Neurology, Neurosurgery & Psychiatry3
BMJ Paediatrics Open2
eGastroenterology2
Journal of Medical Genetics2

Co-occurrence

Explore nearby topics

Inspect the source signal

Article evidence

30 high-ranking examples

Journal for ImmunoTherapy of Cancer · 2025-12-21

TIPE2 deficiency enhances macrophage phagocytosis of tumor cells

Phrase rank #1 · DOI 10.1136/jitc-2025-013425

Journal for ImmunoTherapy of Cancer · 2025-11-04

1191 BPM31510, a CoQ10-lipid nanoparticle, remodels the tumor microenvironment through immuno-metabolic reprogramming in syngeneic models

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1191

Journal for ImmunoTherapy of Cancer · 2025-11-04

377 Decade-long epithelial cancer remissions from cellular therapy

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0377

Journal for ImmunoTherapy of Cancer · 2025-11-04

853 Design of a next generation tumor targeted masked IL-12Fc for enhanced tolerability and localized anti-tumor activity

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0853

Journal for ImmunoTherapy of Cancer · 2025-11-04

942 An mRNA-encoded adjuvant delivered via lipid nanoparticles induces interferon signaling and converts immune cold tumors to hot in patient-derived organotypic tumor spheroids

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0942

Journal for ImmunoTherapy of Cancer · 2025-07-22

Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment

Phrase rank #1 · DOI 10.1136/jitc-2025-011812

Journal for ImmunoTherapy of Cancer · 2026-07-07

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1–NLRC5–MHC-I axis in urothelial carcinoma

Phrase rank #2 · DOI 10.1136/jitc-2026-014770

Gynecology and Obstetrics Clinical Medicine · 2026-06-02

Research progress of lactate and lactylation modification in tumour immunotherapy

Phrase rank #2 · DOI 10.1136/gocm-2024-000183

Journal for ImmunoTherapy of Cancer · 2026-03-03

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

Phrase rank #2 · DOI 10.1136/jitc-2025-013692

Journal for ImmunoTherapy of Cancer · 2026-01-27

Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery

Phrase rank #2 · DOI 10.1136/jitc-2025-012856

Journal for ImmunoTherapy of Cancer · 2025-11-12

Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy

Phrase rank #2 · DOI 10.1136/jitc-2025-012138

Journal for ImmunoTherapy of Cancer · 2025-11-04

410 BTN1A1 blockade enhances chemotherapy-induced anti-tumor immunity in preclinical lung cancer models

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0410

Journal for ImmunoTherapy of Cancer · 2025-11-04

102 New developments in spatial transcriptomics using MERFISH 2.0 unlock insights into the tumor microenvironment

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0102

Journal for ImmunoTherapy of Cancer · 2025-11-04

742 Tumor cells drive spatial organization of the local chemokine milieu within heterogeneous tumors

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0742

Journal for ImmunoTherapy of Cancer · 2025-11-04

1166 Avidity engineered multifunctional antibodies that strongly activate and expand anti-tumor immunity in situ, turning cold patient tumor tissue hot and exerting durable tumor control in mice

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.1166

Journal for ImmunoTherapy of Cancer · 2025-11-04

794 CD163+ macrophages are an effective target for antitumor therapy

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0794

Journal for ImmunoTherapy of Cancer · 2025-11-04

660 A novel TCRβ-directed IL-2 fusion molecule promotes memory CD8+ T cells with self-renewing properties in tumor ecosystems, further expanded by HDAC inhibition to elicit effective tumor suppression

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0660

Journal for ImmunoTherapy of Cancer · 2025-11-04

904 Chemerin suppresses prostate tumor growth by enhancing antigen presentation and effector NK and CD8+ T cell recruitment to the tumor microenvironment

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0904

Journal for ImmunoTherapy of Cancer · 2025-11-04

328 Personalized organoid-based immunotherapy for pancreatic cancer: real-time imaging of cytotoxic lymphocyte-tumor dynamics in an ex vivo model

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0328

Journal for ImmunoTherapy of Cancer · 2025-11-04

663 Epigenetic modulation synergizes with TCRβ-targeted IL-2 to yield CD8+ T cell dependent, MHC-I independent tumor control via an antibody associated mechanism

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0663

Journal for ImmunoTherapy of Cancer · 2025-11-04

1272 EpCAM signaling promotes immunosuppressive tumor microenvironment and a novel therapeutic antibody enhances anti-tumor immunity

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.1272

Journal for ImmunoTherapy of Cancer · 2025-11-04

946 Amphiphile (AMP)-immunomodulator therapy controls growth and eradicates syngeneic solid tumors

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0946

Journal for ImmunoTherapy of Cancer · 2025-11-04

852 AZD6750: design and efficacy of a CD8-guided IL-2 that enhances CD8+ T cell function

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0852

Journal for ImmunoTherapy of Cancer · 2025-11-04

393 DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0393

Journal for ImmunoTherapy of Cancer · 2025-11-04

949 In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human carcinoma expressing truncated core 2 O-glycans

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0949

Journal for ImmunoTherapy of Cancer · 2025-11-04

757 Microphysiological systems to explore the temporal and spatial evolution of natural killer cells in the tumor microenvironment

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0757

Journal for ImmunoTherapy of Cancer · 2025-11-04

989 A multivalent dendrimer-peptide conjugate platform for co-targeting immune checkpoint and oncogenic pathways in HNSCC

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0989

Journal for ImmunoTherapy of Cancer · 2025-11-04

1262 Selective A2aR antagonism restores antitumor immunity in adenosine-enriched tumor microenvironments

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.1262

Journal for ImmunoTherapy of Cancer · 2025-11-04

453 Colocalization of PD-1 and PD-L1 in the tumor compartment predicts checkpoint inhibitor response in melanomas

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0453

Journal for ImmunoTherapy of Cancer · 2025-11-04

610 PD-1-directed intratumoral immunotherapy for cutaneous carcinomas: a clinical study of INTASYL PH-762

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0610